Skip to main content

Table 4 Prognostic factors for progression-free survival (PFS) and overall survival (OS)

From: Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

Variable 2-yearMFS Log-Rank 2-year PFS Log-Rank 2-year OS Log-Rank
Gender
 Male (n = 35) 38.6% p = 0.4 29.5% p = 0.02 49.2% p = 0.9
 Female (n = 11) 55.1%   11.3%   45.7%  
Histology
 Squamous (n = 22) 41.3% p = 0.5 28.6% p = 0.7 31.1% p = 0.2
 Non squamous (n = 24) 60.9%   22.5%   66.5%  
Age
  ≥ 66 years (n = 23) 59.2% p = 0.7 22.5% p = 0.3 31.3% p = 0.02
  < 66 years (n = 23) 47.6%   27.3%   65.7%  
Period between irradiations
  > 24 months (n = 20) 50.9% p = 0.6 18.2% p = 0.5 69.3% p = 0.11
  ≤ 24 months (n = 25) 55.6%   33.4%   37.9%  
Missing value (n = 1)
  > 12 months (n = 36) 59.7% p = 0.3 27.9% p = 0.3 59.5% p = 0.07
  ≤ 12 months (n = 9) 21.4%   18.8%   12.7%  
 Missing value (n = 1)       
Dose of reirradiation
 BED ≤130 Gy (n = 18) 61.1% p = 0.15 28.3% p = 0.2 47.9% p = 0.8
 BED > 130 Gy (n = 28) 44.4%   23%   49.6%  
 BEDmin ≤50 Gy (n = 21) 53% p = 0.3 21.2% p = 0.7 52.9% p = 0.4
 BEDmin > 50 Gy (n = 23) 46.6%   32.2%   42.2%  
SABR duration
  ≥ 6 days (n = 25) 51.9% p = 0.3 21.6% p = 0.3 53% p = 0.6
  < 6 days (n = 20) 54%   30.3%   45.2%  
Number of fractions
  > 3 (n = 30) 50.7% p = 0.5 17.5% p = 0.4 47.1% p = 0.6
  ≤ 3 (n = 16) 56.6%   40.8%   52.1%  
Dose per fraction
  > 12 (n = 23) 45.7% p = 0.4 26.2% p = 0.6 49% p = 0.6
  ≤ 12 (n = 22) 58.8%   24.2%   49.1%  
Chemotherapy after reirradiation
 Yes (n = 10) 50.8% p = 0.9 19% p = 0.5 38.9% p = 0.4
 No (n = 36) 52.6%   27%   51.3%  
Tumor size
  ≥ 33 mm (n = 21) 42.5% p = 0.2 13.7% p = 0.2 31.7% p = 0.059
  < 33 mm (n = 22) 58.9%   31%   69.8%  
 Missing value (n = 3)       
GTV Volume
  ≥ 13 mL (n = 22) 38.4% p = 0.12 13.1% p = 0.10 27.3% p = 0.06
  < 13 mL (n = 22) 58.9%   31%   70.6%  
Missing value (n = 2)       
Performans Status - ECOGa
 0 (n = 27) 57.4% p = 0.3 34.2% p = 0.6 59.9% p = 0.4
 1 (n = 11) 60.6%   21.8%   66.3%  
 Missing value (n = 8)       
Location of relapse
 Central (n = 24) 46.7% p = 0.9 16.5% p = 0.4 43.1% p = 0.2
 Peripheral (n = 22) 59%   35.1%   57.5%  
Primary stage (at first irradiation)
 IIIA (n = 21) 59.7% p = 0.3 30.6% p = 0.3 49.2% p = 0.3
 IIIB (n = 25) 44.4%   21.2%   48.6%  
In-field relapse
 Yes (n = 29) 47.4% p = 0.4 18.3% p = 0.11 42.4% p = 0.11
 No (n = 17) 58.8%   37%   61.1%  
In-field and central tumors
 Yes (n = 19) 45.3% p = 0.9 14.2% p = 4 36.1% p = 0.09
 No (n = 27) 57%   33%   60.8%  
Adjuvant chemotherapy
 No (n = 36) 52.6% p = 0.8 27% p = 0.5 51.3% p = 0.4
 Yes (n = 10) 50.8%   19%   38.9%  
GTV coverage
  < 95% (n = 22) 48.9% p = 0.8 19% p = 0.6 47.2% p = 0.7
  ≥ 95% (n = 24) 54.4%   33.3%   49.9%  
PTV coverage
  < 90% (n = 23) 46.6% p = 0.9 18.2% p = 0.5 44.9% p = 0.9
  ≥ 90% (n = 23) 58.1%   35.6%   52.4%  
  1. aAt time of stereotactic ablative radiotherapy; ECOG = Eastern Cooperative Oncology Group